Discover AAV Tools
High quality & established
Manufacturing antibodies since 1983. DIN EN ISO 13485 Certified and extensively published. All our AAV products are validated by international studies or rigorous internal gold standards.
Easy-to-use tools
Our AAV analytical tools are easy to implement into every workflow. No expensive equipment or special training needed. Products are optimized for a wide range of applications and ready-to-use.
Quick delivery worldwide
Made in Germany. Delivered worldwide. Our off-the-shelf AAV tools can be shipped immediately from Germany or our PROGEN Inc. subsidiary to ensure you get your analytical tools quickly and easily.
On-hand scientific support
We are a team of AAV experts and are partnered with gene therapy experts worldwide. On hand to support you in progressing new AAV gene therapies safely, quickly and affordably.
"Our experience with PROGEN has been overwhelmingly positive and we are impressed with the lengths that PROGEN go to to make AAV related products successful. The PROGEN team are in constant communication and consultation with us and have exceeded our expectations. An extremely professional, remarkably responsive, and technically proficient team."
Lan Chen, Dakewe
News & Stories
From Vision to Legacy: Celebrating 42 Years of PROGEN
In a lab in Heidelberg in 1983, a bold idea to develop new diagnostic reagents and test procedures took root. This October, we celebrate our 42nd anniversary of maintaining the spirit that gave birth to PROGEN and the future we have been creating.
Connecting Science and People
Meet Account Manager Manja von Hahn, who helps scientists worldwide find the right solutions through open conversations and collaboration.
How We Became My Green Lab® Certified: Behind the Scenes at PROGEN
In a field where energy-intensive equipment, single-use plastics, and chemical waste are standard, we asked ourselves: Can we do better?
What We Took Home from ASGCT 2025: Science, Collaboration, and the Spirit of New Orleans
The 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans was an event to remember for its scientific breakthroughs and the city's vibrant energy.
A Quick, Affordable Test for AAVs
Elissa Hudspeth of North Carolina State University shares her experience using a test that has enabled her to more easily set up a manufacturing process for AAVs.
The Road to Transforming Medicine Through AAVs
Adeno-associated virus (AAV) continues to lead the way in gene therapy research. Discover its evolution since the 1960s and its growing role in transforming treatments for both rare and common diseases.
Producing Reliable Products
Meet Head of Production Rita Lacher and discover how she contributes to transforming ideas into new products.
Top 5 Breakthroughs in LNP Research in 2024
From overcoming blood-brain-barrier to more selective delivery, we've seen some truly exciting advancements in the LNP research field.
CRISPR/Cas Meets AAV: Navigating the Complexities of Gene Editing Delivery
The Challenges and Limitations of In Vivo Delivery of CRISPR/Cas Gene Editing Tools
Science in Action
Meet Head of Research and Development Klaus-Ingmar Pfrepper and find out about his team’s recent discovery of a new AAV antibody.
Overcoming Liver Accumulation: Extrahepatic Targeting Strategies for Lipid Nanoparticles (LNPs)
New targeting strategies are showing how the accumulation of lipid nanoparticles (LNPs) in the liver can be reduced.
Beyond the Virus: How Non-Viral Vectors Are Changing Gene Therapy
Lipid nanoparticles (LNPs), are emerging as promising non-viral vectors, offering distinct advantages that could make them integral to the future of gene therapy.
Five Challenges Of Applying Lipid Nanoparticles As Delivery Tools For Therapeutic Agents
As effective as these delivery vehicles are, they come with their own set of difficulties.
Maximizing Efficiency
Getting a transgene to be expressed inside the target cell is the name of the game.
Bringing New Products to Market
Meet Product Manager Silja Adam, whose work on products is motivated by a desire to help customers meet their needs.
The Road To Even Safer AAV Gene Therapies
Although AAVs are among the safest gene therapy vectors, they do pose a few risks that can still be reduced.
Comparability Amid Change
When manufacturing changes bring challenges, standard reference materials can save the day.
Helping people become healthy
Meet PROGEN’s co-CEO Maik Lander and learn more about the importance of meeting customers' needs.
Five Reasons to Choose Adeno-associated Viruses for Gene Therapy
These small but mighty DNA delivery vehicles are revolutionizing medicine
Introducing Recombinant Adeno-associated Viruses (rAAVs)
Modifying AAVs makes them more efficient and better at targeting specific tissues